CancerDrs Find care

Sarcoma clinical trials in Missouri

41 actively recruiting sarcoma trials at 23 sites across Missouri.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting NIH

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with dedifferentiated liposarcoma (DDLPS), undifferentiated pleomorphic sarc…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06422806
Sites in Missouri:
  • Siteman Cancer Center at West County Hospital — Creve Coeur, Missouri
  • Washington University School of Medicine — St Louis, Missouri
  • Siteman Cancer Center-South County — St Louis, Missouri
Phase 3 Recruiting Network

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastase…

Sponsor: Children's Oncology Group
NCT ID: NCT05235165
Sites in Missouri:
  • University of Missouri Children's Hospital — Columbia, Missouri
  • Children's Mercy Hospitals and Clinics — Kansas City, Missouri
  • Cardinal Glennon Children's Medical Center — St Louis, Missouri
  • Washington University School of Medicine — St Louis, Missouri
  • Mercy Hospital Saint Louis — St Louis, Missouri
Phase 2, Phase 3 Recruiting NIH

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

This phase II/III trial tests the safety, side effects, and best dose of the drug cabozantinib in combination with standard chemotherapy, and to compare the effect of adding cabozantinib to standard chemotherapy alone in treating patients …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05691478
Sites in Missouri:
  • University of Missouri Children's Hospital — Columbia, Missouri
  • Children's Mercy Hospitals and Clinics — Kansas City, Missouri
  • Cardinal Glennon Children's Medical Center — St Louis, Missouri
  • Washington University School of Medicine — St Louis, Missouri
  • Mercy Hospital Saint Louis — St Louis, Missouri
Phase 3 Recruiting Network

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

Rhabdomyosarcoma is a type of cancer that occurs in the soft tissues in the body. This phase III trial aims to maintain excellent outcomes in patients with very low risk rhabdomyosarcoma (VLR-RMS) while decreasing the burden of therapy usi…

Sponsor: Children's Oncology Group
NCT ID: NCT05304585
Sites in Missouri:
  • Children's Mercy Hospitals and Clinics — Kansas City, Missouri
  • Cardinal Glennon Children's Medical Center — St Louis, Missouri
  • Washington University School of Medicine — St Louis, Missouri
  • Mercy Hospital Saint Louis — St Louis, Missouri
Phase 3 Recruiting Network

Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyos…

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
NCT ID: NCT04031677
Sites in Missouri:
  • Siteman Cancer Center-West County — Creve Coeur, Missouri
  • Washington University School of Medicine - Siteman Cancer Center — St Louis, Missouri
  • Siteman Cancer Center-South Country — St Louis, Missouri
Phase 3 Recruiting Academic/Other

Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer

This phase III trial compares the effect of sentinel lymph node mapping to standard lymph node dissection in reducing the risk of swelling in the legs (lymphedema) in patients undergoing a hysterectomy for stage I endometrial cancer. Stand…

Sponsor: NRG Oncology
NCT ID: NCT05646316
Sites in Missouri:
  • Mercy Hospital Springfield — Springfield, Missouri
Phase 3 Recruiting Industry

Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

The primary objective of this phase III study is to evaluate whether the combination of lurbinectedin plus doxorubicin given as first line treatment for metastatic leiomyosarcoma (LMS) prolongs the progression-free survival (PFS) by Indepe…

Sponsor: PharmaMar
NCT ID: NCT06088290
Sites in Missouri:
  • Washington University School of Medicine in St. Louis — St Louis, Missouri
Phase 3 Recruiting Industry

Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)

THIS STUDY IS CURRENTLY RECRUITING PATIENTS WITH ALVEOLAR SOFT PART SARCOMA ONLY AND IS NO LONGER RECRUITING PATIENTS WITH SYNOVIAL SARCOMA OR LEIOMYOSARCOMA. This study evaluates the safety and efficacy of AL3818 (anlotinib) hydrochloride…

Sponsor: Advenchen Laboratories, LLC
NCT ID: NCT03016819
Sites in Missouri:
  • Washington University St. Louis — St Louis, Missouri
Phase 3 Recruiting Industry

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral on…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06345729
Sites in Missouri:
  • Truman Medical Center ( Site 0126) — Kansas City, Missouri
  • Cox Medical Center North ( Site 0133) — Springfield, Missouri
Phase 1, Phase 2 Recruiting Industry

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…

Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in Missouri:
  • Local Institution - 2147 — Bolivar, Missouri
  • Washington University Infusion Center Pharmacy — St Louis, Missouri
Phase 1, Phase 2 Recruiting Academic/Other

A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue

The purpose of this study is to determine if the addition of infusions of a type of immune cell called a "natural killer", or NK cell to the sarcoma chemotherapy regimen GEM/DOX (gemcitabine and docetaxel) can improve outcomes in people wi…

Sponsor: Nationwide Children's Hospital
NCT ID: NCT05634369
Sites in Missouri:
  • Washington University/St Louis Childrens — St Louis, Missouri
Phase 1, Phase 2 Recruiting Network

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…

Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Missouri:
  • Washington University School of Medicine — St Louis, Missouri
Phase 1, Phase 2 Recruiting Academic/Other

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

The purpose of this study is to evaluate the investigational drug, silmitasertib (a pill taken by mouth), in combination with FDA approved drugs for solid tumors. An investigational drug is one that has not been approved by the U.S. Food \…

Sponsor: Milton S. Hershey Medical Center
NCT ID: NCT06541262
Sites in Missouri:
  • Children's Mercy Hospitals and Clinics — Kansas City, Missouri
  • Cardinal Glennon Children's Medical Center — St Louis, Missouri
Phase 1, Phase 2 Recruiting Industry

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase…

Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT04094610
Sites in Missouri:
  • Washington University School of Medicine in St. Louis — St Louis, Missouri
Phase 1, Phase 2 Recruiting Industry

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse lar…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06395103
Sites in Missouri:
  • Children's Mercy Hospital ( Site 1024) — Kansas City, Missouri
Phase 2 Recruiting Academic/Other

A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

The purpose of this study is to find out whether selinexor is an effective treatment for people who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPNST, or another solid tumor that makes a higher than normal amount of XPO1 or has…

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT05985161
Sites in Missouri:
  • Washington University — St Louis, Missouri
Phase 2 Recruiting Network

Trial of Ixazomib for Kaposi Sarcoma

This phase II trial studies how well ixazomib works in treating patients with Kaposi sarcoma. Ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Sponsor: AIDS Malignancy Consortium
NCT ID: NCT04305691
Sites in Missouri:
  • Washington University — St Louis, Missouri
Phase 1, Phase 2 Recruiting Industry

SPEARHEAD-3 Pediatric Study

This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A\*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers.

Sponsor: USWM CT, LLC
NCT ID: NCT05642455
Sites in Missouri:
  • Washington University — St Louis, Missouri
Phase 1, Phase 2 Recruiting Academic/Other

Proton or Photon RT for Retroperitoneal Sarcomas

This research study is a Phase I clinical trial. Phase I clinical trials test the safety of an investigational intervention. Phase I studies also try to define the appropriate dose of the investigational therapy to use for further studies.…

Sponsor: Massachusetts General Hospital
NCT ID: NCT01659203
Sites in Missouri:
  • Washington University School of Medicine Siteman Cancer Center West County — Creve Coeur, Missouri
  • Washington University School of Medicine Siteman Cancer Center South County — St Louis, Missouri
Phase 1, Phase 2 Recruiting Academic/Other

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

The study participant has been diagnosed with non-rhabdomyosarcoma (NRSTS). Primary Objectives Intermediate-Risk * To estimate the 3-year event-free survival for intermediate-risk patients treated with ifosfamide, doxorubicin, pazopanib, s…

Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT06239272
Sites in Missouri:
  • Washington University Medical Center — St Louis, Missouri
Phase 2 Recruiting Academic/Other

Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration

This is a single-arm, phase II study that will enroll a total of 45 subjects. All subjects will have a confirmed diagnosis of metastatic or unresectable soft tissue sarcoma or bone sarcoma. All subjects must have intact Rb, identified at t…

Sponsor: Medical College of Wisconsin
NCT ID: NCT04040205
Sites in Missouri:
  • Washington University in St. Louis — St Louis, Missouri
Phase 1, Phase 2 Recruiting Industry

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

Sponsor: Perspective Therapeutics
NCT ID: NCT06710756
Sites in Missouri:
  • Saint Louis University — St Louis, Missouri
Phase 2 Recruiting Academic/Other

Propranolol for the Treatment of Kaposi Sarcoma in Adults

Kaposi sarcoma (KS) lesions are initiated by endothelial cells infected with KS herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8). Lesion progression is driven by abnormal angiogenesis, chronic inflammation, and uncontrolled ce…

Sponsor: Washington University School of Medicine
NCT ID: NCT06445166
Sites in Missouri:
  • Washington University School of Medicine — St Louis, Missouri

Showing 25 of 41 trials with sites in Missouri. See all sarcoma trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20